SRBCF (Sirona Biochem) Cyclically Adjusted PB Ratio: (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Sirona Biochem Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Sirona Biochem  (OTCPK:SRBCF) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Sirona Biochem Cyclically Adjusted PB Ratio Related Terms


Sirona Biochem Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Sirona Biochem's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sirona Biochem Cyclically Adjusted PB Ratio Chart

Sirona Biochem Annual Data
Trend Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.23 0.00 0.00 19.79 23.07

Sirona Biochem Quarterly Data
Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.60 23.07 36.89 36.95 40.31

SRBCF vs MTNB, TCRT, QLGN: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Sirona Biochem's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sirona Biochem Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sirona Biochem's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Sirona Biochem's Cyclically Adjusted PB Ratio falls into.



Sirona Biochem Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Sirona Biochem's Cyclically Adjusted Book per Share for the quarter that ended in Jul. 2024 is calculated as:

For example, Sirona Biochem's adjusted Book Value per Share data for the three months ended in Jul. 2024 was:

Adj_Book=Book Value per Share/CPI of Jul. 2024 (Change)*Current CPI (Jul. 2024)
=-0.01/128.0748*128.0748
=-0.010

Current CPI (Jul. 2024) = 128.0748.

Sirona Biochem Quarterly Data

Book Value per Share CPI Adj_Book
201410 0.012 99.473 0.015
201501 0.007 98.209 0.009
201504 0.009 99.710 0.012
201507 0.010 100.579 0.013
201510 0.011 100.500 0.014
201601 0.011 100.184 0.014
201604 0.012 101.370 0.015
201607 0.010 101.844 0.013
201610 0.007 102.002 0.009
201701 0.005 102.318 0.006
201704 0.002 103.029 0.002
201707 -0.001 103.029 -0.001
201710 -0.010 103.424 -0.012
201801 -0.010 104.056 -0.012
201804 -0.011 105.320 -0.013
201807 -0.010 106.110 -0.012
201810 -0.010 105.952 -0.012
201901 -0.012 105.557 -0.015
201904 -0.005 107.453 -0.006
201907 0.009 108.243 0.011
201910 0.007 107.927 0.008
202001 0.008 108.085 0.009
202004 0.006 107.216 0.007
202007 0.002 108.401 0.002
202010 0.000 108.638 0.000
202101 -0.001 109.192 -0.001
202104 -0.001 110.851 -0.001
202107 -0.002 112.431 -0.002
202110 0.000 113.695 0.000
202201 -0.002 114.801 -0.002
202204 0.003 118.357 0.003
202207 0.003 120.964 0.003
202210 0.001 121.517 0.001
202301 -0.001 121.596 -0.001
202304 -0.002 123.571 -0.002
202307 -0.004 124.914 -0.004
202310 -0.007 125.310 -0.007
202401 -0.008 125.072 -0.008
202404 -0.009 126.890 -0.009
202407 -0.010 128.075 -0.010

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sirona Biochem Business Description

Address C/o WeWork, 595 Burrard Street, Vancouver, BC, CAN, V7X 1L4
Sirona Biochem Corp is a development stage biotechnology company. The principal activities of the company are the development of cosmetic and pharmaceutical active ingredients which are licensed to partners in exchange for upfront, milestone, and royalty payments. The company acts as a cosmetic ingredient and drug discovery company with a proprietary technology platform with a specialization in the stabilization of carbohydrate molecules. The company has a business presence in Canada and France.